It is impossible to compare which side effect is less between Donafenib Methylbenzenesulfonate Tablets and Lenvatinib Mesylate Capsules, it mainly depends on the patient’s personal constitution. Side effects of Donafenib Methylbenzenesulfonate Tablets include alopecia, skin rash, etc. Side effects of Lenvatinib Mesylate Capsules include hypocalcemia. 1. Donafenib mesylate side effects: skin manifestations such as skin reactions on hands and feet, alopecia, rash, etc.; gastrointestinal system manifestations such as diarrhea; lower platelet counts, elevated blood bilirubin, lower white blood cell counts, proteinuria, hypophosphatemia, etc., can be seen in various examinations. This product is suitable for patients with unresectable hepatocellular carcinoma who have not received systemic treatment, and is prohibited for pregnant and lactating women. 2. Lenvatinib mesylate side effects include hypertension, proteinuria, renal failure and renal insufficiency, cardiac dysfunction, hepatotoxicity, arterial thromboembolism. It is used in the treatment of hepatocellular carcinoma and thyroid carcinoma and is contraindicated in lactating women. It is indicated for patients with unresectable hepatocellular carcinoma who have not received systemic treatment and is contraindicated in pregnant and lactating women. If you need to take Donafinil or Lenvatinib, it is recommended to consult with your physician and follow your doctor’s instructions.